Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng-Hua, Wei, Xiao-Li, Feng, Jifeng, Li, Qi, Xu, Nong, Hu, Xi-Chun, Liao, Wangjun, Jiang, Yi, Lin, Xiao-Yan, Zhang, Qing-yuan, Yuan, Xiang-Lin, Huang, Hai-Xin, Chen, Ye, Dai, Guang-Hai, Shi, Jian-Hua, Shen, Lin, Yang, Shu-Jun, Shu, Yong-Qian, Liu, Yun-Peng, Wang, Weifeng, Wu, Hai, Feng, Hui, Yao, Sheng, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
Rapid Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078488/
https://www.ncbi.nlm.nih.gov/pubmed/33492986
http://dx.doi.org/10.1200/JCO.20.02712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078488/
https://www.ncbi.nlm.nih.gov/pubmed/33492986
http://dx.doi.org/10.1200/JCO.20.02712

Ejemplares similares